Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Valeant Pharmaceuticals (VRX), CBS Corporation (CBS) and Sirius XM Holdings (SIRI) Pushed This Hedgie to 11.5% Q1 Returns

Page 1 of 2

The equity portfolio of Peter Adam Hochfelder’s Brahman Capital enjoyed a strong first quarter, with its 13 long positions in companies valued at $1 billion or more delivering weighted average returns of 11.5% during the period. A number of the New York-based fund’s top picks performed well in early 2015, including one of its small-cap picks, which actually performed so well that it pushed itself out of small-cap distinction during the quarter.

CBS Corporation (NYSE:CBS)

It’s investors like Hochfelder who add great value to our small-cap strategy system, as they are heavily invested in the success of their small-cap picks and have poured considerable resources into identifying undervalued or under-the-radar companies to invest in. We have found that collectively, hedge funds’ top small-cap picks provide a great investment opportunity, with our strategy having returned over 137% since it was launched at the end of August 2012, outperforming the market by more than 82 percentage points through the end of March (see the details).

We’ll get to that former small-cap pick later, but let’s start first with the fund’s top pick, Calpine Corporation (NYSE:CPN), which delivered solid if unspectacular returns of 3.34% for the quarter. Brahman’s position in Calpine Corporation (NYSE:CPN)was increased by 57% during the fourth quarter to 26.65 million shares valued at $589.73 million. The fund’s exposure to the stock also more than doubled during the fourth quarter to 16.79% from 8.12%, given the increased stake as well as the decline in the overall value of Brahman’s equity portfolio to $3.51 billion from $4.56 billion. Luminus Management was another fund bullish on Calpine Corporation (NYSE:CPN) during the fourth quarter, increasing its stake by 17%. While the overall number of funds invested in Calpine at the end of 2014 remained the same as at the end of the previous quarter, at 35, the amount of capital they had invested in the stock increased by more than 25%, which can’t be accounted for by the value of Calpine’s shares, which only rose 2% during the fourth quarter, so there was some very strong bullish sentiment on Calpine. Shares of the power generation company are now up by 15.83% over the past six months.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was one of the strongest performing large-cap stocks of the first quarter, thanks in large part to the Canadian pharmaceutical company’s purchase of Salix Pharmaceuticals for $11.1 billion in February. Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) skyrocketed by 38.79% as a result, which was great news for Brahman Capital, as it held a 3.69 million share position in Valeant worth $528.69 million entering the year; now worth considerably more. However, the fund might be kicking itself slightly after reducing its position in Valeant, which had previously been its top long position for over three years running, by 18% during the fourth quarter. Nehal Chopra’s Tiger Ratan enjoyed a monster quarter thanks to increasing her position in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) by 47% during the fourth quarter, lifting her exposure to the stock to over 28%.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!